Evaluation of Long-Acting Lenacapavir for the Treatment of HIV-1 in Treatment-experienced Adolescents and Children
Phase 2
12
about 2.1 years
≤17
1 site in GA
About this study
Researchers are testing a new treatment, lenacapavir (LEN), to see if it's safe and effective in children and adolescents who have already been treated for HIV. The trial will evaluate how well LEN works when combined with other medicines, either as an injection or an oral pill.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Subcutaneous Lenacapavir
- 2.Take Optimized Background Regimen (OBR)
- 3.Take Oral Lenacapavir
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
lenacapavir
injection, subcutaneous, oral
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) Through Week 26, Pharmacokinetic (PK) Parameter: Ctrough, W26 of Lenacapavir (LEN)
Secondary: Change From Baseline in CD4+ Cell Counts at Week 52, Change From Baseline in Clusters of Differentiation (CD4)+ Cell Counts at Week 26, PK Parameter: AUC D1-W26 of LEN, PK Parameter: Cmax, D1-W26 of LEN, Percent Change From Baseline in CD4+ at Week 26, Percent Change From Baseline in CD4+ at Week 52, Percentage of Participants Experiencing Treatment-Emergent AEs Through Week 52
Immune, Infectious